Objectives:

1. Review the evidence that lead to designation of alteplase as “Class 1 Level A evidence” in the management of acute ischemic stroke for patients presenting between 0-3 hours;
2. Review the evidence that lead to designation of alteplase as “Class 1 Level B evidence” in the management of acute ischemic stroke for patients presenting between 3-4.5 hours; and
3. Review statistical methods used in the two major thrombolysis trials for acute ischemic stroke.

 

Session date: 
Thursday, December 7, 2017 - 3:00pm to 4:00pm
Location: 
UCMC
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.